Allergy Relief (Fexofenadine Hydrochrloride) Tablets USP, 180 mg, packaged in a) 15-count cartons...
FDA Drug Recall #D-1865-2019 — Class II — August 23, 2019
Recall Summary
| Recall Number | D-1865-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 23, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Aurolife Pharma, LLC |
| Location | Dayton, NJ |
| Product Type | Drugs |
| Quantity | a) 9662 cartons; b) 7382 cartons; c) 5184 cartons; d) 9842 cartons |
Product Description
Allergy Relief (Fexofenadine Hydrochrloride) Tablets USP, 180 mg, packaged in a) 15-count cartons (NDC 60000-409-53); b) 30-count cartons (NDC 60000-409-30); c) 45-count bonus cartons (NDC 60000-409-48); d) 45-count cartons (NDC 60000-409-45); CAREone, Distributed by: Foodhold U.S.A., LLC, Landover, MD 20785.
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot #s: a) 067180025D1, Exp 07/21; b) 067180025B1, Exp 07/21; c) 067180025A1, Exp 07/21; d) 067180025C1, Exp 07/21
Other Recalls from Aurolife Pharma, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0877-2023 | Class III | Glycopyrrolate Tablets, USP, 1 mg, 100-count bo... | May 18, 2023 |
| D-0087-2023 | Class II | Glycopyrrolate Tablets, USP, 1 mg, 100 tablets,... | Dec 16, 2022 |
| D-0736-2022 | Class II | Glycopyrrolate Tablets, USP, 1 mg, 100-count bo... | Mar 17, 2022 |
| D-1864-2019 | Class II | Fexofenadine Hydrochrloride Tablets USP, 180 mg... | Aug 23, 2019 |
| D-1868-2019 | Class II | Fexofenadine Hydrochloride Tablets USP, 180 mg,... | Aug 23, 2019 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.